July 31, 2018
A recipe related to Janssen Biotech Inc.'s blockbuster immunosuppressant Remicade was too obvious for any competitor to have legally infringed a patent on it, a Massachusetts federal judge ruled Tuesday, allowing Pfizer Inc. to rest easy about the validity of its new-to-market equivalent to treat arthritis and psoriasis among other common conditions.
March 03, 2017
Biosimilar makers must satisfy each step of the Biologics Price Competition and Innovation Act's "patent dance" if they hope to reduce damages that innovator companies can seek for infringement, a Massachusetts federal judge said in a newly released opinion.
March 01, 2017
A Massachusetts federal judge has ruled that biosimilar makers must engage in good-faith talks with innovator counterparts in order to trigger a litigation deadline for innovators to seek lost profits, according to representatives of Janssen Biotech and Pfizer.
June 17, 2016
Janssen Biotech Inc. on Thursday asked a Massachusetts federal court to combine two patent cases it's bringing against Celltrion Healthcare Co. and Hospira Inc. over Inflectra, the defendants' biosimilar of Janssen's blockbuster immunosuppressant Remicade.